ACXP · Acurx Pharmaceuticals, Inc. · Exempt Offerings
$1.43
-0.01 (-0.35%)
At close · Sep 9
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed Aug 13, 2026
Market Cap
$7.48M
Shares
5.27M
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2026-04-29 | New | Pharmaceuticals | $4,587,473 | $4,587,473 | 06b |
| 2025-06-27 | New | Pharmaceuticals | $3,978,664 | $3,978,664 | 06b |
| 2025-05-20 | New | Pharmaceuticals | $12,000,000 | $0 | 06b |
| 2025-03-21 | New | Pharmaceuticals | $3,376,350 | $3,376,350 | 06b |
| 2025-01-17 | New | Pharmaceuticals | $2,404,259 | $2,404,259 | 06b |
| 2020-01-17 | New | Biotechnology | $6,000,000 | $455,000 | 06b |
Showing 1–6 of 6 filings
Key facts
CIK
1736243
CUSIP
00510M203
13F (30d)
13 filings
13 filers
Visit website
Investor relations